NCT03206229 - Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

February 13, 2017

Primary Completion Date

June 2, 2017

Study Completion Date

January 18, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

PEG-rhG-CSF

PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule

DRUG

Neulasta (PEG-rhG-CSF)

PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule

Trial Locations (1)

WCCT Global Inc., Cypress